1 Market Overview

1.1 Product Overview and Scope of Targeted Drugs for Breast Cancer

1.2 Classification of Targeted Drugs for Breast Cancer by Type

1.2.1 Overview: Global Targeted Drugs for Breast Cancer Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2021

1.2.3 HER-2 Targeted Drugs

1.2.4 CDK4/6 Inhibitors

1.2.5 PARP Targeted Drugs

1.2.6 PI3K/AKT/mTor Pathway Inhibitors

1.2.7 ER Targeted Drugs

1.2.8 Aromatase Inhibitors

1.2.9 Tubulin Inhibitors

1.2.10 VEGF Targeted Drugs

1.2.11 YTMS Targeted Drugs

1.2.12 Other

1.3 Global Targeted Drugs for Breast Cancer Market by Application

1.3.1 Overview: Global Targeted Drugs for Breast Cancer Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Drug Center

1.3.5 Other

1.4 Global Targeted Drugs for Breast Cancer Market Size & Forecast

1.5 Global Targeted Drugs for Breast Cancer Market Size and Forecast by Region

1.5.1 Global Targeted Drugs for Breast Cancer Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Targeted Drugs for Breast Cancer Market Size by Region, (2017-2022)

1.5.3 North America Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)

1.5.4 Europe Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)

1.5.6 South America Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Targeted Drugs for Breast Cancer Market Drivers

1.6.2 Targeted Drugs for Breast Cancer Market Restraints

1.6.3 Targeted Drugs for Breast Cancer Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Targeted Drugs for Breast Cancer Product and Solutions

2.1.4 Roche Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Roche Recent Developments and Future Plans

2.2 Teva

2.2.1 Teva Details

2.2.2 Teva Major Business

2.2.3 Teva Targeted Drugs for Breast Cancer Product and Solutions

2.2.4 Teva Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Teva Recent Developments and Future Plans

2.3 Mylan

2.3.1 Mylan Details

2.3.2 Mylan Major Business

2.3.3 Mylan Targeted Drugs for Breast Cancer Product and Solutions

2.3.4 Mylan Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Mylan Recent Developments and Future Plans

2.4 Hikma

2.4.1 Hikma Details

2.4.2 Hikma Major Business

2.4.3 Hikma Targeted Drugs for Breast Cancer Product and Solutions

2.4.4 Hikma Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Hikma Recent Developments and Future Plans

2.5 Hengrui Medicine

2.5.1 Hengrui Medicine Details

2.5.2 Hengrui Medicine Major Business

2.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Product and Solutions

2.5.4 Hengrui Medicine Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Hengrui Medicine Recent Developments and Future Plans

2.6 Cipla

2.6.1 Cipla Details

2.6.2 Cipla Major Business

2.6.3 Cipla Targeted Drugs for Breast Cancer Product and Solutions

2.6.4 Cipla Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Cipla Recent Developments and Future Plans

2.7 Reliance Group

2.7.1 Reliance Group Details

2.7.2 Reliance Group Major Business

2.7.3 Reliance Group Targeted Drugs for Breast Cancer Product and Solutions

2.7.4 Reliance Group Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Reliance Group Recent Developments and Future Plans

2.8 Hetero

2.8.1 Hetero Details

2.8.2 Hetero Major Business

2.8.3 Hetero Targeted Drugs for Breast Cancer Product and Solutions

2.8.4 Hetero Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Hetero Recent Developments and Future Plans

2.9 Pfizer

2.9.1 Pfizer Details

2.9.2 Pfizer Major Business

2.9.3 Pfizer Targeted Drugs for Breast Cancer Product and Solutions

2.9.4 Pfizer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Pfizer Recent Developments and Future Plans

2.10 Eli Lilly

2.10.1 Eli Lilly Details

2.10.2 Eli Lilly Major Business

2.10.3 Eli Lilly Targeted Drugs for Breast Cancer Product and Solutions

2.10.4 Eli Lilly Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Eli Lilly Recent Developments and Future Plans

2.11 Novartis

2.11.1 Novartis Details

2.11.2 Novartis Major Business

2.11.3 Novartis Targeted Drugs for Breast Cancer Product and Solutions

2.11.4 Novartis Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Novartis Recent Developments and Future Plans

2.12 CANbridge

2.12.1 CANbridge Details

2.12.2 CANbridge Major Business

2.12.3 CANbridge Targeted Drugs for Breast Cancer Product and Solutions

2.12.4 CANbridge Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 CANbridge Recent Developments and Future Plans

2.13 Puma Biotechnology

2.13.1 Puma Biotechnology Details

2.13.2 Puma Biotechnology Major Business

2.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Product and Solutions

2.13.4 Puma Biotechnology Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Puma Biotechnology Recent Developments and Future Plans

2.14 AstraZeneca

2.14.1 AstraZeneca Details

2.14.2 AstraZeneca Major Business

2.14.3 AstraZeneca Targeted Drugs for Breast Cancer Product and Solutions

2.14.4 AstraZeneca Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 AstraZeneca Recent Developments and Future Plans

2.15 Chugai Pharmaceutical

2.15.1 Chugai Pharmaceutical Details

2.15.2 Chugai Pharmaceutical Major Business

2.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

2.15.4 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Chugai Pharmaceutical Recent Developments and Future Plans

2.16 Eisai

2.16.1 Eisai Details

2.16.2 Eisai Major Business

2.16.3 Eisai Targeted Drugs for Breast Cancer Product and Solutions

2.16.4 Eisai Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Eisai Recent Developments and Future Plans

2.17 GlaxoSmithKline

2.17.1 GlaxoSmithKline Details

2.17.2 GlaxoSmithKline Major Business

2.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Product and Solutions

2.17.4 GlaxoSmithKline Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 GlaxoSmithKline Recent Developments and Future Plans

2.18 Bristol-Myers Squibb

2.18.1 Bristol-Myers Squibb Details

2.18.2 Bristol-Myers Squibb Major Business

2.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product and Solutions

2.18.4 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.19 Otsuka Pharmaceutical

2.19.1 Otsuka Pharmaceutical Details

2.19.2 Otsuka Pharmaceutical Major Business

2.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

2.19.4 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Otsuka Pharmaceutical Recent Developments and Future Plans

2.20 Merck

2.20.1 Merck Details

2.20.2 Merck Major Business

2.20.3 Merck Targeted Drugs for Breast Cancer Product and Solutions

2.20.4 Merck Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Merck Recent Developments and Future Plans

2.21 BioMarin

2.21.1 BioMarin Details

2.21.2 BioMarin Major Business

2.21.3 BioMarin Targeted Drugs for Breast Cancer Product and Solutions

2.21.4 BioMarin Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 BioMarin Recent Developments and Future Plans

2.22 Hengrui Pharmaceutical

2.22.1 Hengrui Pharmaceutical Details

2.22.2 Hengrui Pharmaceutical Major Business

2.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

2.22.4 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Hengrui Pharmaceutical Recent Developments and Future Plans

2.23 Beijing Biostar Technologies

2.23.1 Beijing Biostar Technologies Details

2.23.2 Beijing Biostar Technologies Major Business

2.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product and Solutions

2.23.4 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 Beijing Biostar Technologies Recent Developments and Future Plans

2.24 Bayer

2.24.1 Bayer Details

2.24.2 Bayer Major Business

2.24.3 Bayer Targeted Drugs for Breast Cancer Product and Solutions

2.24.4 Bayer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Bayer Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Targeted Drugs for Breast Cancer Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Targeted Drugs for Breast Cancer Players Market Share in 2021

3.2.2 Top 10 Targeted Drugs for Breast Cancer Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided

3.4 Targeted Drugs for Breast Cancer Mergers & Acquisitions

3.5 Targeted Drugs for Breast Cancer New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2017-2022)

4.2 Global Targeted Drugs for Breast Cancer Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2017-2022)

5.2 Global Targeted Drugs for Breast Cancer Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)

6.2 North America Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)

6.3 North America Targeted Drugs for Breast Cancer Market Size by Country

6.3.1 North America Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)

6.3.2 United States Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

6.3.3 Canada Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

6.3.4 Mexico Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)

7.2 Europe Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)

7.3 Europe Targeted Drugs for Breast Cancer Market Size by Country

7.3.1 Europe Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)

7.3.2 Germany Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

7.3.3 France Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

7.3.5 Russia Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

7.3.6 Italy Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)

8.2 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)

8.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region

8.3.1 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Region (2017-2028)

8.3.2 China Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8.3.3 Japan Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8.3.4 South Korea Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8.3.5 India Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

8.3.7 Australia Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)

9.2 South America Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)

9.3 South America Targeted Drugs for Breast Cancer Market Size by Country

9.3.1 South America Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)

9.3.2 Brazil Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

9.3.3 Argentina Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)

10.2 Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)

10.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country

10.3.1 Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)

10.3.2 Turkey Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

10.3.4 UAE Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Targeted Drugs for Breast Cancer Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Targeted Drugs for Breast Cancer Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Targeted Drugs for Breast Cancer Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Targeted Drugs for Breast Cancer Revenue (USD Million) by Region (2017-2022)

Table 5. Global Targeted Drugs for Breast Cancer Revenue Market Share by Region (2023-2028)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Targeted Drugs for Breast Cancer Product and Solutions

Table 9. Roche Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Teva Corporate Information, Head Office, and Major Competitors

Table 11. Teva Major Business

Table 12. Teva Targeted Drugs for Breast Cancer Product and Solutions

Table 13. Teva Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Mylan Corporate Information, Head Office, and Major Competitors

Table 15. Mylan Major Business

Table 16. Mylan Targeted Drugs for Breast Cancer Product and Solutions

Table 17. Mylan Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Hikma Corporate Information, Head Office, and Major Competitors

Table 19. Hikma Major Business

Table 20. Hikma Targeted Drugs for Breast Cancer Product and Solutions

Table 21. Hikma Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Hengrui Medicine Corporate Information, Head Office, and Major Competitors

Table 23. Hengrui Medicine Major Business

Table 24. Hengrui Medicine Targeted Drugs for Breast Cancer Product and Solutions

Table 25. Hengrui Medicine Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Cipla Corporate Information, Head Office, and Major Competitors

Table 27. Cipla Major Business

Table 28. Cipla Targeted Drugs for Breast Cancer Product and Solutions

Table 29. Cipla Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Reliance Group Corporate Information, Head Office, and Major Competitors

Table 31. Reliance Group Major Business

Table 32. Reliance Group Targeted Drugs for Breast Cancer Product and Solutions

Table 33. Reliance Group Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Hetero Corporate Information, Head Office, and Major Competitors

Table 35. Hetero Major Business

Table 36. Hetero Targeted Drugs for Breast Cancer Product and Solutions

Table 37. Hetero Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Pfizer Corporate Information, Head Office, and Major Competitors

Table 39. Pfizer Major Business

Table 40. Pfizer Targeted Drugs for Breast Cancer Product and Solutions

Table 41. Pfizer Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 43. Eli Lilly Major Business

Table 44. Eli Lilly Targeted Drugs for Breast Cancer Product and Solutions

Table 45. Eli Lilly Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Novartis Corporate Information, Head Office, and Major Competitors

Table 47. Novartis Major Business

Table 48. Novartis Targeted Drugs for Breast Cancer Product and Solutions

Table 49. Novartis Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. CANbridge Corporate Information, Head Office, and Major Competitors

Table 51. CANbridge Major Business

Table 52. CANbridge Targeted Drugs for Breast Cancer Product and Solutions

Table 53. CANbridge Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Puma Biotechnology Corporate Information, Head Office, and Major Competitors

Table 55. Puma Biotechnology Major Business

Table 56. Puma Biotechnology Targeted Drugs for Breast Cancer Product and Solutions

Table 57. Puma Biotechnology Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 59. AstraZeneca Major Business

Table 60. AstraZeneca Targeted Drugs for Breast Cancer Product and Solutions

Table 61. AstraZeneca Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 63. Chugai Pharmaceutical Major Business

Table 64. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

Table 65. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Eisai Corporate Information, Head Office, and Major Competitors

Table 67. Eisai Major Business

Table 68. Eisai Targeted Drugs for Breast Cancer Product and Solutions

Table 69. Eisai Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 71. GlaxoSmithKline Major Business

Table 72. GlaxoSmithKline Targeted Drugs for Breast Cancer Product and Solutions

Table 73. GlaxoSmithKline Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 75. Bristol-Myers Squibb Major Business

Table 76. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product and Solutions

Table 77. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Otsuka Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 79. Otsuka Pharmaceutical Major Business

Table 80. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

Table 81. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Merck Corporate Information, Head Office, and Major Competitors

Table 83. Merck Major Business

Table 84. Merck Targeted Drugs for Breast Cancer Product and Solutions

Table 85. Merck Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. BioMarin Corporate Information, Head Office, and Major Competitors

Table 87. BioMarin Major Business

Table 88. BioMarin Targeted Drugs for Breast Cancer Product and Solutions

Table 89. BioMarin Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Hengrui Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 91. Hengrui Pharmaceutical Major Business

Table 92. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product and Solutions

Table 93. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. Beijing Biostar Technologies Corporate Information, Head Office, and Major Competitors

Table 95. Beijing Biostar Technologies Major Business

Table 96. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product and Solutions

Table 97. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Bayer Corporate Information, Head Office, and Major Competitors

Table 99. Bayer Major Business

Table 100. Bayer Targeted Drugs for Breast Cancer Product and Solutions

Table 101. Bayer Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Global Targeted Drugs for Breast Cancer Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 103. Global Targeted Drugs for Breast Cancer Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 104. Breakdown of Targeted Drugs for Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)

Table 105. Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided

Table 106. Targeted Drugs for Breast Cancer Mergers & Acquisitions in the Past Five Years

Table 107. Targeted Drugs for Breast Cancer New Entrants and Expansion Plans

Table 108. Global Targeted Drugs for Breast Cancer Revenue (USD Million) by Type (2017-2022)

Table 109. Global Targeted Drugs for Breast Cancer Revenue Share by Type (2017-2022)

Table 110. Global Targeted Drugs for Breast Cancer Revenue Forecast by Type (2023-2028)

Table 111. Global Targeted Drugs for Breast Cancer Revenue by Application (2017-2022)

Table 112. Global Targeted Drugs for Breast Cancer Revenue Forecast by Application (2023-2028)

Table 113. North America Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)

Table 114. North America Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)

Table 115. North America Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)

Table 116. North America Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)

Table 117. North America Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)

Table 118. North America Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)

Table 119. Europe Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)

Table 120. Europe Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)

Table 121. Europe Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)

Table 122. Europe Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)

Table 123. Europe Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)

Table 124. Europe Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)

Table 125. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)

Table 126. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)

Table 127. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)

Table 128. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)

Table 129. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Region (2017-2022) & (USD Million)

Table 130. Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Region (2023-2028) & (USD Million)

Table 131. South America Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)

Table 132. South America Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)

Table 133. South America Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)

Table 134. South America Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)

Table 135. South America Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)

Table 136. South America Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)

Table 137. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)

Table 138. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)

Table 139. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)

Table 140. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)

Table 141. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)

Table 142. Middle East & Africa Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Targeted Drugs for Breast Cancer Picture

Figure 2. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2021

Figure 3. HER-2 Targeted Drugs

Figure 4. CDK4/6 Inhibitors

Figure 5. PARP Targeted Drugs

Figure 6. PI3K/AKT/mTor Pathway Inhibitors

Figure 7. ER Targeted Drugs

Figure 8. Aromatase Inhibitors

Figure 9. Tubulin Inhibitors

Figure 10. VEGF Targeted Drugs

Figure 11. YTMS Targeted Drugs

Figure 12. Other

Figure 13. Targeted Drugs for Breast Cancer Revenue Market Share by Application in 2021

Figure 14. Hospital Picture

Figure 15. Clinic Picture

Figure 16. Drug Center Picture

Figure 17. Other Picture

Figure 18. Global Targeted Drugs for Breast Cancer Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 19. Global Targeted Drugs for Breast Cancer Revenue and Forecast (2017-2028) & (USD Million)

Figure 20. Global Targeted Drugs for Breast Cancer Revenue Market Share by Region (2017-2028)

Figure 21. Global Targeted Drugs for Breast Cancer Revenue Market Share by Region in 2021

Figure 22. North America Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. Europe Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. Asia-Pacific Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)

Figure 25. South America Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)

Figure 26. Middle East and Africa Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)

Figure 27. Targeted Drugs for Breast Cancer Market Drivers

Figure 28. Targeted Drugs for Breast Cancer Market Restraints

Figure 29. Targeted Drugs for Breast Cancer Market Trends

Figure 30. Roche Recent Developments and Future Plans

Figure 31. Teva Recent Developments and Future Plans

Figure 32. Mylan Recent Developments and Future Plans

Figure 33. Hikma Recent Developments and Future Plans

Figure 34. Hengrui Medicine Recent Developments and Future Plans

Figure 35. Cipla Recent Developments and Future Plans

Figure 36. Reliance Group Recent Developments and Future Plans

Figure 37. Hetero Recent Developments and Future Plans

Figure 38. Pfizer Recent Developments and Future Plans

Figure 39. Eli Lilly Recent Developments and Future Plans

Figure 40. Novartis Recent Developments and Future Plans

Figure 41. CANbridge Recent Developments and Future Plans

Figure 42. Puma Biotechnology Recent Developments and Future Plans

Figure 43. AstraZeneca Recent Developments and Future Plans

Figure 44. Chugai Pharmaceutical Recent Developments and Future Plans

Figure 45. Eisai Recent Developments and Future Plans

Figure 46. GlaxoSmithKline Recent Developments and Future Plans

Figure 47. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 48. Otsuka Pharmaceutical Recent Developments and Future Plans

Figure 49. Merck Recent Developments and Future Plans

Figure 50. BioMarin Recent Developments and Future Plans

Figure 51. Hengrui Pharmaceutical Recent Developments and Future Plans

Figure 52. Beijing Biostar Technologies Recent Developments and Future Plans

Figure 53. Bayer Recent Developments and Future Plans

Figure 54. Global Targeted Drugs for Breast Cancer Revenue Share by Players in 2021

Figure 55. Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 56. Global Top 3 Players Targeted Drugs for Breast Cancer Revenue Market Share in 2021

Figure 57. Global Top 10 Players Targeted Drugs for Breast Cancer Revenue Market Share in 2021

Figure 58. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 59. Global Targeted Drugs for Breast Cancer Revenue Share by Type in 2021

Figure 60. Global Targeted Drugs for Breast Cancer Market Share Forecast by Type (2023-2028)

Figure 61. Global Targeted Drugs for Breast Cancer Revenue Share by Application in 2021

Figure 62. Global Targeted Drugs for Breast Cancer Market Share Forecast by Application (2023-2028)

Figure 63. North America Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)

Figure 64. North America Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)

Figure 65. North America Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)

Figure 66. United States Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Canada Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Mexico Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Europe Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)

Figure 70. Europe Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)

Figure 71. Europe Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)

Figure 72. Germany Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. France Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. United Kingdom Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Russia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Italy Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Asia-Pacific Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)

Figure 78. Asia-Pacific Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)

Figure 79. Asia-Pacific Targeted Drugs for Breast Cancer Revenue Market Share by Region (2017-2028)

Figure 80. China Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Japan Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. South Korea Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. India Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. Southeast Asia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Australia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 86. South America Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)

Figure 87. South America Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)

Figure 88. South America Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)

Figure 89. Brazil Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 90. Argentina Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 91. Middle East and Africa Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)

Figure 92. Middle East and Africa Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)

Figure 93. Middle East and Africa Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)

Figure 94. Turkey Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 95. Saudi Arabia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 96. UAE Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 97. Methodology

Figure 98. Research Process and Data Source